Shares of pharmaceutical company Aptinyx (NASDAQ: APTX) rallied in after-hours trading following the company’s announcement of positive topline results from its Phase 2 study of NYX-783 in patients with post-traumatic stress disorder (PTSD).
Aptinyx stated that NYX-783 demonstrated “statistically significant” results and a “favourable adverse event and tolerability profile.”
The primary endpoint of the study was achieved with both dose levels demonstrating a statistically significant improvement in patients.
“We expect the data from this study will support discussion with the FDA and the initiation of a first pivotal study. In addition, these results provide further clinical validation of our NMDA receptor modulation platform and reinforce our confidence in its therapeutic utility across our other clinical-stage programs in chronic pain and cognition,” commented Norbert Riedel, Aptinyx’s President and CEO.
The company said that they now plan to submit the study results for publication and presentation at scientific and medical meetings.
Aptinyx’s stock price surged 91.53% to $7.01 after the news was released on Monday evening. It closed the regular session at $3.66 per share.